 |
|
|
|
|
As the founder and CEO of cardiabase, and after 10 years of active involvement in clinical research, I am proud to offer a complete set of cardiac safety services.
|
|
|
|
|
|
|
|
|
|
These services are supported by a multidisciplinary team including cardiac technicians, IT professionals, data managers, specialists in logistics, quality assurance and regulatory affairs, as well as a dozen of cardiologists. All members of staff join their efforts to develop innovative solutions and guarantee data quality and integrity, always within the agreed timelines. Cardiac Safety is a critical area of clinical research, and has been our profession since 1999.
Dr. P. Wicker, a cardiologist with 20+ years of drug development experience in a major international pharmaceutical company, has recently joined our team and will contribute its expertise and knowledge to help you design the most time and cost efficient cardiovascular safety assessment program.
To make a long story short, whenever you think of Cardiac Safety and Efficacy (assessment strategy, protocol design, ECG, Holter, CABPM, Pace Maker or ICD, CEC of Adjudication Committee management), please feel free to contact us!
|
|
|
 |
|
| Dr. Pascal Voiriot (CMO) |
|
|
|
|
|
|
|
|
|
Dr. Pascal Voiriot graduated from Nancy University, France in 1980. He specialized in Internal Medicine (Infectious Diseases) and Cardiology, and has been involved in drug evaluations since 1989 as a consultant for the French Medicine Agency (AFSSAPS). In 1999, he founded cardiabase, a cardiac safety core lab based in Nancy (France). He is currently the CMO of cardiabase.
|
|
|
|
|
|
|
|
|
|
Dr. Pierre Wicker is a Board-Certified Cardiologist who received his MD degree from the University of Bordeaux, France. In 1984 he moved to the Cleveland Clinic Foundation before joining the pharmaceutical industry in 1989. At Pfizer, Dr. Wicker managed several development programs from early discovery to phase III, mostly in the cardiovascular area. Over the past decade, he has acquired a unique expertise in cardiovascular safety and QT assessment, first as a member and then as co-chair of the Pfizer Cardiovascular Safety Council. Since he left Pfizer in 2007, Dr.Wicker has been working as a consultant to the pharmaceutical industry.
|
|
|
|
|
